Effect of bevacizumab treatment on p-boronophenylalanine distribution in murine tumor

Journal of Radiation Research

Volumn 54, Issue 2, 2013, Pages 260-267

  Liu, Yong ^a,b   Suzuki, Minoru ^b   Masunaga, Shin Ichiro ^b   Chen, Yi Wei ^c   Kashino, Genro ^d   Tanaka, Hiroki ^b   Sakurai, Yoshinori ^b   Kirihata, Mitsunori ^e   Ono, Koji ^b  

^a FUDAN UNIVERSITY   (China)

^b KYOTO UNIVERSITY   (Japan)

^c TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^d OITA UNIVERSITY   (Japan)

^e Osaka Prefecture University   (Japan)

Author keywords

angiogenesis inhibitor; bevacizumab; BNCT; boron compounds

Indexed keywords

CELL CULTURE; FLUORESCENCE; GAMMA RAY SPECTROMETERS; GAMMA RAYS;

ANGIOGENESIS INHIBITORS; AVASTIN; BEVACIZUMAB; BORON DISTRIBUTION; BORON NEUTRON CAPTURE THERAPY; BORON NEUTRONCAPTURE THERAPY; IMMUNOFLUORESCENCE STAINING; INHIBITORY EFFECT; TUMOR MODELS; TUMOR VESSELS;

TUMORS;

EID: 84874822082     PISSN: 04493060     EISSN: 13499157     Source Type: Journal    
DOI: 10.1093/jrr/rrs102     Document Type: Article

References (28)

1. Pisarev MA, Dagrosa MA, Juvenal GJ. Boron neutron capture therapy in cancer: past, present and future. Arq Bras Endocrinol Metabol 2007;51:852-6.
2. Kageji T, Mizobuchi Y, Nagahiro S, et al. Clinical results of boron neutron capture therapy (BNCT) for glioblastoma. Appl Radiat Isot 2011;69:1823-5.
3. Kageji T, Mizobuchi Y, Nagahiro S, et al. Long-survivors of glioblatoma treated with boron neutron capture therapy (BNCT). Appl Radiat Isot 2011;69:1800-2.
4. Coderre JA, Turcotte JC, Riley KJ, et al. Boron neutron capture therapy: cellular targeting of high linear energy transfer radiation. Technol Cancer Res Treat 2003;2:355-75.
5. De Bock K, Cauwenberghs S, Carmeliet P. Vessel abnormalization: another hallmark of cancer? Molecular mechanisms therapeutic implications. Curr Opin Genet Dev 2011;21: 73-9.
6. Shih T, Lindley C. Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies. Clin Ther 2006;28:1779- 802.
7. Waldner MJ, Neurath MF. Targeting the VEGF signaling pathway in cancer therapy. Expert Opin Ther Targets 2012;16: 5-13.
8. Ferrara N, Hillan KJ, Novotny W. Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem Biophys Res Commun 2005;333:328-35.
9. Ranieri G, Patruno R, Ruggieri E, et al. Vascular endothelial growth factor (VEGF) as a target of bevacizumab in cancer: from the biology to the clinic. Curr Med Chem 2006;13: 1845-57.
10. Fukumura D, Jain RK. Tumor microvasculature and microenvironment: targets for anti-angiogenesis and normalization. Microvasc Res 2007;74:72-84.
11. Inoue N, Kusumoto M, Nakazawa M, et al. The making of BPA monoclonal antibody and the analysis of its primary structure. The program of the 4th meeting of Japan boron neutron capture therapy. 2007;23.
12. Tabata C, Kadokawa Y, Tabata R, et al. All-transretinoic acid prevents radiation- or bleomycin-induced pulmonary fibrosis. Am J Repair Crit Care Med 2006;174:1352-60.
13. Yamamoto T, Nakai K, Matsumura A. Boron neutron capture therapy for glioblastoma. Cancer Lett 2008;262:143-52.
14. Kato I, Fujita Y, Maruhashi A, et al. Effectiveness of boron neutron capture therapy for recurrent head and neck malignancies. Appl Radiat Isot 2009;67:S37-42.
15. Barth RF. Boron neutron capture therapy at the crossroads: challenges and opportunities. Appl Radiat Isot 2009;67:S3-6.
16. Kumar S, Freytag SO, Barton KN, et al. A novel method of boron delivery using sodium iodide symporter for boron neutron capture therapy. J Radiat Res 2010;51:621-6.
17. Nakamura H. Liposomal boron delivery for neutron capture therapy. Methods Enzymol 2009;465:179-208.
18. Jain RK. Barriers to drug delivery in solid tumors. Sci Am 1994;271:58-65.
19. McDonald DM, Baluk P. Significance of blood vessel leakiness in cancer. Cancer Res 2002;62:5381-5.
20. Bikfalvi A, Moenner M, Javerzat S, et al. Inhibition of angiogenesis and the angiogenesis/invasion shift. Biochem Soc Trans 2011;39:1560-4.
21. Shinkaruk S, Bayle M, Laïn G, Déléris G. Vascular endothelial cell growth factor (VEGF), an emerging target for cancer chemotherapy. Curr Med Chem Anticancer Agents 2003;3:95-117.
22. Pircher A, Hilbe W, Heidegger I, et al. Biomarkers in tumor angiogenesis and anti-angiogenic therapy. Int J Mol Sci 2011;12: 7077-99.
23. Masunaga S, Liu Y, Tanaka H, et al. Reducing intratumour acute hypoxia through bevacizumab treatment, referring to the response of quiescent tumour cells and metastatic potential. Br J Radiol 2011;84:1131-8.
24. Dings RP, Loren M, Heun H, et al. Scheduling of radiation with angiogenesis inhibitors anginex and Avastin improves therapeutic outcome via vessel normalization. Clin Cancer Res 2007;13:3395-402.
25. Molinari AJ, Pozzi EC, Monti Hughes A, et al. Tumor blood vessel 'normalization' improves the therapeutic efficacy of boron neutron capture therapy (BNCT) in experimental oral cancer. Radiat Res 2012;177:59-68.
26. Hamzah J, Jugold M, Kiessling F, et al. Vascular normalization in Rgs5-deficient tumours promotes immune destruction. Nature 2008;453:410-14.
27. Chae SS, Kamoun WS, Farrar CT, et al. Angiopoietin-2 interferes with anti-VEGFR2-induced vessel normalization and survival benefit in mice bearing gliomas. Clin Cancer Res 2010;16:3618-27.
28. Kaelin WG, Jr, Ratcliffe PJ. Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. Mol Cell 2008;30:393-402.